Vaccine Conjugates Market Size Report- Growth, Challenges, and Top Key Players
Global Vaccine
Conjugates Market Size Overview
Conjugate
vaccines are developed through a covalent bond between a weak antigen and a
strong antigen. This boosts the immune response of the host towards various
diseases. Conjugate vaccines are germ specific and are capable of identifying
just the targeted germs and bacteria, making them usable as a preventive
measure to provide additional protection.
The global
vaccine conjugates market is anticipated to register a 14.5% CAGR over the
forecast period of 2018-2027. Various factors attributable to such growth
include a rising occurrence of diseases caused by various microorganisms and
bacteria. Further, a mounting awareness towards the prevention and avoidance of
infectious diseases is driving the global vaccine conjugates market to a great
extent. An increasing number of regulatory approvals to a rising number of
vaccines is expected to ascend the global vaccine conjugates market by 2027.
However, complex
manufacturing procedures and low accessibility of vaccines to rural and remote
areas are anticipated to hinder growth in the global vaccine conjugates market.
Moreover, recent incidents of fraud and malpractice of top vaccine
manufacturers are assessed to refrain the market from augmenting during the
forecast period. For instance, in July 2018, a Chinese vaccine manufacturer was
found guilty of fabricating its manufacturing records and faced legal
consequences.
Get Sample
Report: https://www.marketresearchfuture.com/sample_request/1107
Market Segmentation
The global
vaccine conjugates market is studied by Market Research Future (MRFR) for
various segments. This segmentation is carried out by type, disease indication,
patient stage, pathogen type, end-user, and region. Based on type, the vaccine
conjugates market is segmented into multivalent conjugate vaccines and
monovalent conjugate vaccines. On the basis of disease indication, the vaccine
conjugates market is segmented into influenza, DTP, pneumococcal, and
meningococcal. Based on pathogen type, the vaccine conjugates market is
segmented into bacterial conjugate vaccine, viral conjugate vaccine, and
combination conjugate vaccine. Based on patient stage, the vaccine conjugates
market is segmented into adults conjugate vaccine and pediatrics conjugate
vaccine. Based on end-user, the vaccine conjugates market has been segmented
into academic institutes, research institutes, and pharmaceutical industries.
Detailed Regional Analysis
The global
vaccine conjugates market is segmented into the regions of the Americas,
Europe, Asia Pacific, and the Middle East and Africa. Among these regions, the
Americas are expected to spearhead the global vaccine conjugates market during
the forecast period. This market command can be accredited to the rising
prevalence of infectious diseases and increasing awareness of vaccination.
Further, technological advancements and rising government initiatives towards
the encouragement of vaccination programs are contributing to the heavy
ascension of the vaccine conjugates market. The Centers for Disease Control
(CDC) has mentioned that vaccination has proven as the best medium towards the
prevention of diseases and has reduced the impact of various life-threatening
diseases.
On the other
hand, Europe’s vaccine conjugates market is highly driven by extensive research
and development activities in the fields of biotechnology and vaccine
conjugates within various countries in the region. The vaccine conjugates
market in the region is expected to register faster growth and is anticipated
to follow the Americas. Owing to the rising demand for genetically modified
organisms, the market in Europe is showcasing huge growth potential during the
forecast period.
Asia Pacific is
anticipated to grow at a steady rate for vaccine conjugates during the forecast
period. This can be owed to a growing prevalence of geriatric population and
the prevalence of infectious diseases. Countries such as Singapore, India,
China, and Japan are projected to showcase extraordinary growth opportunities
for vaccine conjugate providers during the forthcoming years. Medical
institutes in Asia Pacific are primarily focusing on the use of vaccine
conjugates and numerous research and development activities over for the same.
Key Players
The report by MRFR
on global vaccine conjugates market has mentioned many prominent players in the
market including GlaxoSmithKline plc (U.K.), Pfizer, Inc. (U.S.), Merck &
Co., Inc. (U.S.), Sanofi Pasteur SA (France), CSL Limited (Australia), Emergent
BioSolutions, Inc. (U.S.), Johnson & Johnson (U.S.), Medimmune, LLC (U.S.),
Astellas Pharma Inc. (Japan), Serum Institute of India (India), Bavarian Nordic
(Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), Daiichi Sankyo
Company, Limited (Japan), Fablife. (India), SutroVax Inc. (U.S), and Sinovac
Biotech Ltd. (China).
Industry Update
June 2019:
Novavax has entered into a strategic partnership with Catalent Biologics to
expand their gene therapy footprint. Novavax is a biotechnology company that
develops next-generation vaccines for serious infectious diseases. Catalent Biologics develops and manufactures
gene therapies as well as antibody-drug conjugates.
Report
Details@ https://www.marketresearchfuture.com/reports/vaccine-conjugates-market-1107
About US:
Market Research
Future (MRFR) enable customers to unravel the complexity of various industries
through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw
Research Reports (3R), Continuous-Feed Research (CFR), and Market Research
& Consulting Services.
Contact us:
Market Research
Future (part of Wantstats Research and Media Private Limited),
99 Hudson
Street,5Th Floor, New York,
New York 10013
Comments
Post a Comment